News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Harvard Apparatus Regenerative Technology Files Pre-IND Meeting Documents And Orphan Biologics Application With U.S. FDA


1/6/2014 8:28:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has filed its pre-Investigational New Drug (IND) meeting documents with the U.S. Food and Drug Administration (FDA). The company expects the pre-IND meeting to take place by the end of January 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES